Ignite Creation Date:
2024-05-05 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 9:48 AM
Study NCT ID:
NCT00665327
Status:
COMPLETED
Last Update Posted:
2014-11-18
First Post:
2008-04-18
Brief Title:
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was to assess the safety of sequential intravenous IVoral PO moxifloxacin Avelox compared with sequential IVPO levofloxacin Levaquin in the treatment of elderly subjects aged 8805 65 years with community-acquired pneumonia CAP who required initial IV therapy This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None